AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study

Abstract

Aims/hypothesis The hypoglycaemic actions of metformin have been proposed to be mediated by hepatic AMP-activated protein kinase (AMPK). As the effects of metformin and the role of AMPK in adipose tissue remain poorly characterised, we examined the effect of metformin on AMPK activity in adipose tissue of individuals with type 2 diabetes in a randomised glycaemia-controlled crossover study. Methods Twenty men with type 2 diabetes (aged 50-70 years) treated with diet, metformin or sulfonylurea alone were recruited from North Glasgow University National Health Service Trusts' diabetes clinics and randomised to either metformin or gliclazide for 10 weeks. Randomisation codes, generated by computer, were put into sealed envelopes and stored by the hospital pharmacist. Medication bottles were numbered, and allocation was done in sequence. The participants and investigators were blinded to group assignment. At the end of each phase of therapy adipose biopsy, AMPK activity (primary endpoint) and levels of lipid metabolism and signalling proteins were assessed. In parallel, the effect of metformin on AMPK and insulinsignalling pathways was investigated in 3T3-L1 adipocytes. Results Ten participants were initially randomised to metformin and subsequently crossed over to gliclazide, while ten participants were initially randomised to gliclazide and subsequently crossed over to metformin. No participants discontinued the intervention and the adipose tissue AMPK activity was analysed in all 20 participants. There were no adverse events or side effects in the study group. Adipose AMPK activity was increased following metformin compared with gliclazide therapy (0. ; p< 0.005), independent of AMPK level, glycaemia or plasma adiponectin concentrations. The increase was associated with reduced levels of acetyl-CoA carboxylase (ACC) protein and increased ACC Ser80 phosphorylation. In 3T3-L1 adipocytes, metformin reduced levels of ACC protein and stimulated phosphorylation of AMPK Thr172 and hormone-sensitive lipase Ser565. Conclusions These results provide the first evidence that metformin activates AMPK and reduces ACC protein levels in human adipose tissue in vivo. Future studies are required to assess the role of adipose AMPK activation in the pharmacological effects of metformin.Trial registration ISRCTN51336867

Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1/PI3K/Akt and AMPK/ACC2 signaling pathways

“…It has been known that the inhibitory effects of metformin on fatty acid metabolism occur via preferential AMPK-α 1 phosphorylation in rat muscle cells [55] . More recently, Boyle [56] found that metformin activates AMPK and reduces ACC protein levels in human adipose tissue in vivo. Our data indicated that rutaecarpine and metformin potentially act on the same pathway to regulate lipid metabolism.…”

The expression of genes involved in jejunal lipogenesis and lipoprotein synthesis is altered in morbidly obese subjects with insulin resistance

“…39 However, our results are not according to research made in 3T3-L1 adipocytes, in which metformin reduces ACC1 protein. 40 These differences could be due to the fact that the regulation of the metabolism of different tissues may differ. Together, our results show a slight beneficial effect of metformin on the restitution of intestinal lipid/lipoprotein homeostasis.…”

Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue

“…Also of note, more of the insulin resistant than insulin sensitive patients enrolled in our study were on metformin therapy. However, the use of this drug has been shown to increase AMPK activity in adipose tissue ( 49 ). Thus, if anything, this would have made for higher rather than lower AMPK activity in the insulin resistant subjects.…”